Press ReleaseView printer-friendly version << Back
Audentes Therapeutics Appoints Eric B. Mosbrooker as Senior Vice President and Chief Commercial Officer
"Eric is an established leader with a demonstrated track-record of building global commercial organizations and successfully launching rare disease products," stated
Mr. Mosbrooker has held numerous leadership roles throughout his more than 15 years in the healthcare industry, with the majority of his tenure focused on launching and commercializing treatments for rare and orphan diseases. Mr. Mosbrooker joins Audentes from Origin Biosciences, a subsidiary of BridgeBio Pharma and a biotechnology company focused on developing a treatment for molybdenum cofactor deficiency (MoCD) type A, a rare pediatric metabolic disorder, where he served as Chief Operating Officer. Prior to Origin Biosciences, Mr. Mosbrooker led the orphan business at
"This is an exciting time to join Audentes," stated Mr. Mosbrooker. "I look forward to building and leading a top-tier commercial organization that can deliver innovative therapies with the potential to provide transformative benefit to patients."
In connection with Mr. Mosbrooker's appointment, effective
For more information regarding Audentes, please visit www.audentestx.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: the timing and nature of clinical development activities, the timing of regulatory submissions or approvals, and the expected safety and efficacy profile of the company's product candidates. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Although the company believes that the expectations reflected in such forward-looking statements are reasonable, the company cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval is inherently uncertain. Forward-looking statements are subject to risks and uncertainties that may cause the company's actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the company's ability to advance its product candidates, obtain regulatory approval of and ultimately commercialize its product candidates, the timing and results of preclinical and clinical trials, the company's ability to fund development activities and achieve development goals, establish and scale-up manufacturing processes that comply with regulatory requirements, protect intellectual property and other risks and uncertainties described under the heading "Risk Factors" in documents the company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.
View original content to download multimedia:http://www.prnewswire.com/news-releases/audentes-therapeutics-appoints-eric-b-mosbrooker-as-senior-vice-president-and-chief-commercial-officer-300770424.html